BEVERLY HILLS, Calif.,
June 8, 2021 /PRNewswire/ -- GT
Biopharma, Inc. ("GT Biopharma" or the "Company") (NASDAQ: GTBP), a
clinical stage immuno-oncology company focused on developing
innovative therapeutics based on the Company's proprietary natural
killer (NK) cell engager (TriKE™) protein biologic technology
platform, today announced that it is set to be added to the Russell
2000® Index at the conclusion of the Russell US
Indexes annual reconstitution, effective at the opening of the U.S.
equity markets on June 28, 2021.
"Our inclusion in the Russell index is an important milestone
for us as it reflects the continued progress we are making to
develop and commercialize our first-in-class therapeutics. We
welcome the enhanced visibility of our long-term growth potential
and look forward to sharing our future milestones with a broader
investment community," said Anthony J.
Cataldo, GT Biopharma's Chairman and Chief Executive
FTSE Russell determines membership for its Russell indexes
primarily by objective, market-capitalization rankings and style
attributes. Membership in the small-cap Russell
2000® Index, which remains in place for one year,
is based on membership in the broad-market Russell
Russell's U.S. indexes are widely used by investment managers
and institutional investors for index funds and as benchmarks for
active investment strategies. Approximately $9 trillion in assets are benchmarked against
Russell's U.S. indexes. Russell Indexes are part of FTSE Russell, a
leading global index provider.
For more information about the Russell U.S. Indexes and
the Russell Indexes reconstitution, visit the FTSE Russell
About GT Biopharma, Inc.
GT Biopharma, Inc. is a
clinical stage biopharmaceutical company focused on the development
and commercialization of immuno-oncology therapeutic products based
on our proprietary TriKE™ NK cell engager platform. Our
TriKE™ platform is designed to harness and enhance the cancer
killing abilities of a patient's immune system's natural killer
cells (NK cells). GT Biopharma has an exclusive worldwide
license agreement with the University of
Minnesota to further develop and commercialize therapies
using TriKE™ technology. For more information, please visit
Investor and Media
View original content to download
SOURCE GT Biopharma, Inc.